Literature DB >> 8067901

Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver.

F Montandon1, G M Williams.   

Abstract

The polyphenylethylene estrogenic drug diethylstilbestrol and a structural analogue tamoxifen have been found to be hepatocarcinogenic in female rats, whereas another analogue, toremifene, did not induce liver tumors. The 32P post-labelling technique for detection of DNA adducts was used to investigate the DNA reactivity of these three hormonal agents in the livers of female Sprague-Dawley rats and Syrian hamsters. Adducts were quantified using a radioanalytic imaging system in comparison with the standard Cerenkov assay. With administration of the chemicals at several doses by daily gavage to rats for 10 days and to hamsters for 7 days, tamoxifen was found to produce five adducts in rat liver and six adducts in hamster liver. The amounts of adducts were dose related from 10 to 90 mumol/kg per day in rats and from 17 to 160 mumol/kg per day in hamsters. The two methods of quantification yielded comparable results. Under these conditions, neither toremifene nor diethylstilbestrol produced adducts in rats and diethylstilbestrol produced none in hamsters. We conclude that tamoxifen is highly DNA reactive in the species studied and that this is likely to be involved in its strong carcinogenicity in rat liver.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8067901     DOI: 10.1007/s002040050068

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  19 in total

Review 1.  Epigenetic mechanisms of liver tumor promotion.

Authors:  G M Williams
Journal:  Prog Clin Biol Res       Date:  1990

2.  Mechanism of genotoxicity of diethylstilbestrol in vivo.

Authors:  A Gladek; J G Liehr
Journal:  J Biol Chem       Date:  1989-10-05       Impact factor: 5.157

Review 3.  Studies on the mechanism of carcinogenicity of diethylstilboestrol: role of metabolic activation.

Authors:  M Metzler
Journal:  Food Cosmet Toxicol       Date:  1981-10

4.  Nuclease P1-mediated enhancement of sensitivity of 32P-postlabeling test for structurally diverse DNA adducts.

Authors:  M V Reddy; K Randerath
Journal:  Carcinogenesis       Date:  1986-09       Impact factor: 4.944

Review 5.  Review of the pharmacological properties of toremifene.

Authors:  L Kangas
Journal:  J Steroid Biochem       Date:  1990-06-22       Impact factor: 4.292

6.  Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats.

Authors:  G C Hard; M J Iatropoulos; K Jordan; L Radi; O P Kaltenberg; A R Imondi; G M Williams
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

7.  Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation.

Authors:  C Mani; D Kupfer
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

8.  Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells.

Authors:  I N White; F de Matteis; A Davies; L L Smith; C Crofton-Sleigh; S Venitt; A Hewer; D H Phillips
Journal:  Carcinogenesis       Date:  1992-12       Impact factor: 4.944

9.  Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens.

Authors:  P Hirsimäki; Y Hirsimäki; L Nieminen; B J Payne
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

10.  32P-labeling test for DNA damage.

Authors:  K Randerath; M V Reddy; R C Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

View more
  4 in total

Review 1.  Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 2.  Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk.

Authors:  Mitchell S Steiner; Sharan Raghow
Journal:  World J Urol       Date:  2003-02-14       Impact factor: 4.226

3.  Chicken fetal liver DNA damage and adduct formation by activation-dependent DNA-reactive carcinogens and related compounds of several structural classes.

Authors:  Gary M Williams; Jian-Dong Duan; Klaus D Brunnemann; Michael J Iatropoulos; Esther Vock; Ulrich Deschl
Journal:  Toxicol Sci       Date:  2014-06-27       Impact factor: 4.849

4.  Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.

Authors:  S Pyrhönen; R Valavaara; H Modig; M Pawlicki; T Pienkowski; S Gundersen; J Bauer; G Westman; S Lundgren; G Blanco; O Mella; I Nilsson; T Hietanen; I Hindy; J Vuorinen; A Hajba
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.